Project Grant P01CA285250
Award Date
9/13/24
Completion Date
8/31/29
Dollars Obligated
$2.8M
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
This Project Grant award from the National Institute on Aging (NIA) under CFDA 93.866, Aging Research, aims to investigate how epigenetic deregulation of osteoblasts (bone cells) promotes age-related clonality in hematopoietic cells. The $1,335,986 award to The Trustees of Columbia University in the City of New York, with a performance period from Aug 2024 to Apr 2029, will support research to: Delineate how epigenetically modified mouse and human stromal cells and osteoblasts promote the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports fundamental research aimed at understanding the biological mechanisms underlying acute myeloid leukemia (AML) development and progression. The $487,973 award to The Leland Stanford Junior University will fund a 5-year project investigating the role of pre-leukemic hematopoietic stem cells (pHSCs) in AML pathogenesis. The research will explore the clonal evolution, kinetics, and cell...
This Project Grant award from the National Cancer Institute (CFDA 93.396, Cancer Biology Research) provides $680,334 to the Icahn School of Medicine at Mount Sinai to conduct research aimed at understanding the fundamental biological mechanisms underlying age-associated pathogenic myelopoiesis and its contribution to increased cancer risk and progression in aging populations. The 5-year study will utilize high-dimensional profiling, multi-omics phenotyping, and complex bone marrow experiments to...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to understand the fundamental biological mechanisms underlying acute myeloid leukemia (AML). The $483,760 award, effective April 1, 2025 through March 31, 2030, will enable The Trustees of the University of Pennsylvania to investigate the role of the DCAF15 E3 ligase in regulating the cohesin complex and genome architecture in AML. Key objectives include deciphering the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $439,644 to The Leland Stanford Junior University to conduct functional studies on human acute myeloid leukemia (AML) stem cells. The key objectives are to: 1) Investigate the relationship between specific genetic mutations and AML stem cell frequency, disease initiation, and disease maintenance by correcting mutations in primary AML cells and AML-induced pluripotent stem cells (iPSCs);...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $590,960.00 in funding to the Beckman Research Institute of the City of Hope to conduct research aimed at improving the understanding and treatment of acute myeloid leukemia (AML). The key objectives of the project are to: 1) Quantify the dynamics of leukemia potential driven by different oncogenic signals in murine models, 2) Evaluate the effects of treatment on leukemia...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $458,698 to the Regents of the University of Michigan to conduct research aimed at understanding the fundamental biological mechanisms underlying acute myeloid leukemia (AML) relapse. The research will focus on identifying novel gene drivers that confer therapy resistance and contribute to the competitive regrowth of leukemic cells after initial treatment, which is a major barrier...
This five-year $360,281 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Biology Research program (CFDA 93.396). The grantee, Washington University, will conduct studies to define the contribution of altered epigenetic patterns and genome organization to the pathogenesis of acute myeloid leukemia (AML). Researchers will perform comprehensive epigenetic analysis of DNA methylation and three-dimensional...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Case Western Reserve University to investigate a novel combination therapy approach for acute myeloid leukemia (AML). The $491,357 award, granted on March 15, 2025, aims to establish the mechanistic role of mTOR hyperactivation as a chemosensitizer for AML. Key objectives include mapping mitochondrial respiratory defects, identifying AML cell susceptibility to metabolic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $542,663 to The University of Texas M.D. Anderson Cancer Center to conduct preclinical research on novel therapies for acute myeloid leukemia (AML). The research aims to evaluate the efficacy of BRG1/BRM antagonists, such as the inhibitor FHD-286 and the degrader AU15330, in overcoming resistance to menin inhibitors in AML with MLL rearrangement or mutant NPM1. The studies...